Teva Pharmaceutical Industries Ltd. has secured U.S. Food and Drug Administration approval for Weltruza, an extended-release olanzapine suspension administered once monthly by subcutaneous injection for adults with schizophrenia. Teva plans to make the drug available in the United States in the coming weeks in 318 mg, 425 mg and 531 mg strengths, with no loading doses, oral supplementation or mandatory post-injection monitoring required.
The approval gives Teva a differentiated way to use one of psychiatry’s most established antipsychotics in a long-acting formulation while avoiding an important operational limitation associated with the older intramuscular olanzapine depot Zyprexa Relprevv. That medicine carries requirements linked to post-injection delirium/sedation syndrome, including administration through a restricted program and observation after dosing. Weltruza’s label still acknowledges that PDSS has occurred with intramuscular extended-release olanzapine and states that it is not known whether the syndrome can occur with Weltruza, so the absence of mandatory post-injection monitoring should not be interpreted as evidence that the risk is impossible.
The regulatory decision also strengthens Teva’s attempt to shift its product mix toward proprietary growth medicines. Shares closed October 9 at $41.10, up 4.7%, on volume of about 14.8 million shares compared with 5.8 million the previous session, while the company’s long-acting schizophrenia franchise already includes Uzedy, the extended-release risperidone injection approved in 2023.
Why does removing post-injection monitoring materially change long-acting olanzapine delivery?
Olanzapine has long been used because of its antipsychotic efficacy, but translating the molecule into a practical long-acting injectable has historically been complicated by post-injection delirium/sedation syndrome. Zyprexa Relprevv carries a boxed warning covering PDSS and must be administered in a registered healthcare facility with access to emergency services, with patients monitored for at least three hours after each injection. Those requirements can create a substantial workflow burden for outpatient psychiatry clinics, healthcare professionals and patients receiving repeated maintenance treatment.
Weltruza uses a subcutaneous depot rather than the intramuscular formulation used for Zyprexa Relprevv. Teva developed it with Medincell’s SteadyTeq copolymer technology, which is designed to release olanzapine gradually over the monthly dosing interval. In the completed SOLARIS program, Teva reported no suspected or confirmed PDSS events across approximately 3,470 active injections through long-term follow-up.
That clinical experience supported a label without the mandatory post-injection observation requirement attached to the older olanzapine depot. The practical implication could be significant because a monthly treatment that does not require several hours of observation may be easier to integrate into community mental-health services and routine outpatient visits, although the actual impact will depend on reimbursement, clinic capacity, prescribing habits and patient acceptance.
The FDA-approved safety information remains deliberately more cautious than a simple claim that the problem has been eliminated. Weltruza’s prescribing information warns about PDSS observed with another extended-release olanzapine injection and makes clear that whether the syndrome can occur with the subcutaneous product is unknown. The commercially important distinction is therefore the absence of a required observation period, not proof that a rare post-injection risk can never occur.
What did the 675-patient SOLARIS Phase 3 trial establish about Weltruza efficacy?
SOLARIS was a multinational, multicenter, randomized, double-blind, placebo-controlled Phase 3 study enrolling 675 adults with schizophrenia during its eight-week controlled efficacy period. Participants were randomized equally to monthly doses of 318 mg, 425 mg or 531 mg of the long-acting olanzapine formulation or placebo, followed by an open-label safety period extending for as long as another 48 weeks.
The primary endpoint measured change in Positive and Negative Syndrome Scale total score at Week 8. Teva reported placebo-adjusted mean differences of approximately 9.7 points for the 531 mg group, 11.3 points for the 425 mg group and 9.7 points for the 318 mg group, with all three comparisons statistically significant. Key secondary measures examining Clinical Global Impression-Severity and Personal and Social Performance also met their multiplicity-adjusted statistical objectives.
Those findings establish that the monthly formulation produced statistically significant symptom improvement compared with placebo during the controlled study period. They should not be interpreted as showing superiority over oral olanzapine or other long-acting antipsychotics because SOLARIS was not designed as a head-to-head efficacy trial against those treatments.
Longer-term follow-up was used primarily to characterize maintenance of effect and tolerability. Teva later reported a mean 7.2-point improvement in PANSS total score from the start of the open-label period and a 4.6-point increase in Personal and Social Performance score across the active-treatment groups, while clinical effectiveness was maintained during extended treatment.
How does Weltruza preserve olanzapine’s efficacy while retaining its metabolic trade-offs?
The new formulation changes how olanzapine is delivered, not the pharmacological identity of the medicine. That means Weltruza carries many of the safety considerations already familiar from systemic olanzapine use, including clinically meaningful weight gain and metabolic changes. Teva reported that increased weight, somnolence, headache, constipation and injection-site reactions were among the most common adverse events observed during SOLARIS.
Long-term SOLARIS data illustrate the issue more clearly. Among participants receiving the long-acting formulation for at least 48 weeks, Teva reported an average weight increase of 5.6 kilograms, which the company described as comparable with experience from other olanzapine formulations. Across active treatment groups, 36% of participants experienced increased weight as a treatment-emergent adverse event, while serious adverse events occurred in 6% and treatment-emergent adverse events leading to discontinuation occurred in 8%.
The approval therefore does not remove one of the main clinical considerations associated with olanzapine. Prescribers still need to balance antipsychotic effectiveness against weight gain, glucose and lipid effects and other established risks, particularly for patients with pre-existing cardiometabolic vulnerability.
Weltruza also carries the class boxed warning regarding increased mortality in elderly patients with dementia-related psychosis and is not approved for that population. Its commercial differentiation is principally about sustained drug delivery and treatment logistics, rather than a fundamentally different systemic safety profile from olanzapine.
Why could avoiding oral supplementation make Weltruza easier to initiate?
Long-acting injectable antipsychotics differ considerably in how they are started. Some require oral antipsychotic supplementation while therapeutic concentrations build, loading regimens involving additional injections, or other initiation steps that can complicate switching from oral treatment.
Weltruza reaches its approved maintenance approach without a loading dose or oral olanzapine supplementation. The 318 mg, 425 mg and 531 mg monthly doses correspond to approved oral olanzapine maintenance doses of 10 mg, 15 mg and 20 mg per day, respectively.
Reducing initiation complexity could matter in schizophrenia care because treatment continuity can be difficult when patients move between hospitals, outpatient services and community settings. A regimen that does not require clinicians to coordinate temporary oral supplementation may simplify implementation, although the choice of antipsychotic still depends on previous response, tolerability, comorbidities and individual clinical circumstances.
The advantage also needs to be separated from adherence outcomes that were not directly established by the pivotal placebo-controlled study. Monthly administration makes missed treatment easier for care teams to identify than daily tablet use, but SOLARIS was not designed to prove that Weltruza reduces hospitalization, relapse or long-term nonadherence compared with oral olanzapine or competing long-acting injectables.
How does Weltruza fit alongside Uzedy in Teva’s expanding schizophrenia franchise?
Weltruza is the second FDA-approved medicine generated through Teva’s collaboration with French drug-delivery specialist Medincell. The first, Uzedy, uses the same broader long-acting delivery technology platform to provide extended-release risperidone for adults with schizophrenia and was approved in the United States in 2023.
Uzedy has already developed into a meaningful commercial product for Teva. Second-quarter 2026 U.S. revenue reached $77 million, up 43% from the same period a year earlier, while first-half sales totaled $140 million, up 51%. Teva consequently increased its 2026 Uzedy revenue outlook to between $270 million and $290 million.
Weltruza expands that franchise without simply duplicating Uzedy. Risperidone and olanzapine have different efficacy, tolerability and patient-selection considerations, allowing Teva to offer two long-acting antipsychotic molecules using related depot technology rather than relying on a single product.
Commercially, the strategy also gives Teva an existing schizophrenia sales and payer infrastructure into which Weltruza can be introduced. Uzedy’s growth provides evidence that Teva can build demand for a differentiated long-acting injectable, but it does not establish the eventual adoption rate for Weltruza, which will enter a market with multiple long-acting antipsychotic choices and a well-known olanzapine metabolic profile.
What does the approval mean financially for Medincell’s partnership with Teva?
Medincell retains an economic interest in Weltruza through its licensing arrangement with Teva. The French company said it is entitled to mid-single-digit to high-single-digit royalties on worldwide net sales and could receive up to $112 million in development and commercial milestone payments associated with the product.
The FDA approval triggers a $4 million payment, while up to $105 million of the total potential milestone package is tied to achievement of specified sales thresholds. The remainder of the headline value should not be treated as money already received because most of the economics depend on future commercial performance.
For Medincell, Weltruza is particularly important because it becomes the second marketed validation of its long-acting injectable platform after Uzedy. Its shares resumed trading on Euronext Paris after being temporarily suspended pending the announcement, and market data showed a sharp positive reaction following the regulatory news.
The partnership structure allows Teva to lead development and commercialization while Medincell participates through royalties and milestones without carrying the full expense of a U.S. commercial launch. That model becomes more valuable if multiple licensed depot products progress successfully through development rather than depending on a single marketed asset.
Why did Teva stock rise after the Weltruza decision?
Teva shares closed at $41.10 on October 9, up 4.7%, after reaching an intraday high above $42. Trading volume increased to roughly 14.8 million shares from about 5.8 million the previous session, indicating a clear rise in market attention around the approval.
The reaction needs to be viewed in the context of Teva’s broader strategy rather than as a valuation assigned exclusively to Weltruza. Teva’s key innovative medicines, Austedo, Ajovy and Uzedy, generated more than $1 billion of combined second-quarter revenue and grew 43% year over year in local-currency terms, while lower U.S. generic revenue continued to pressure another major part of the business.
Weltruza adds another proprietary product at a time when Teva is trying to increase the proportion of revenue generated by differentiated medicines. The company still needs to establish payer access, physician uptake and prescription growth before the approval can be translated into a dependable new revenue stream.
Analyst expectations around the product are substantial, but forecasts remain forecasts. The more reliable commercial signals will come from launch access, reimbursement coverage, treatment starts and quarterly sales once Weltruza becomes available in the United States.
What will determine whether Weltruza changes routine schizophrenia treatment?
Teva expects U.S. availability in the coming weeks, moving the product rapidly from regulatory approval into its commercial execution phase. Launch performance will depend on whether psychiatrists see enough practical value in monthly subcutaneous olanzapine to switch appropriate patients from oral therapy or other long-acting injectables, and whether insurers provide access without creating administrative barriers.
The strongest practical argument is unusually clear: Weltruza combines established olanzapine pharmacology with once-monthly dosing while avoiding loading doses, oral supplementation and mandatory post-injection observation. That combination could remove several operational frictions that previously limited the attractiveness of long-acting olanzapine.
Its limitations are equally clear. Metabolic effects remain part of the treatment profile, the FDA label does not state that PDSS is impossible with the subcutaneous formulation, and the pivotal study demonstrated placebo-controlled symptom improvement rather than superiority to competing long-acting antipsychotics.
The European regulatory process could provide the next geographic expansion opportunity. The European Medicines Agency accepted Teva’s marketing authorization application for the long-acting olanzapine formulation in May 2026, but the medicine has not yet received European marketing authorization.
Weltruza’s FDA approval therefore removes a major development risk while opening a more demanding commercial test. Teva has succeeded in making long-acting olanzapine substantially easier to administer from a workflow perspective; the next question is whether psychiatrists, payers and mental-health systems value that convenience enough to build a second large product alongside Uzedy without losing sight of the metabolic monitoring that remains inseparable from systemic olanzapine treatment.
